Resource Center
Explore Resource Types
We have housed the technical documents (SDS, COAs, Manuals and more) in a dedicated section.
Explore all All Resources
Filters
Select resource types
Select products & services
Select solutions (2)
Active Filters (2)
Clear All
157 - 164 of 164 Results
Sort by:
Best Match
Application Note
Performing AlphaLISA assays with RPMI-1640
This application note provides alternatives for working with samples in RPMI medium, which contains high levels of biotin
Literature - Publication Review
Current approaches to identify possible COVID-19 therapeutics
Current approaches to identify possible COVID-19 treatment strategies fall into one of three categories: Antivirals, antibodies, or protein-protein interaction inhibitors.
Whitepaper
An emerging therapeutic modality - RNA carves its path out of the paradigm
Learn more about several promising classes of RNA therapeutic, including RNAi, CRISPR, base editing, and mRNA vaccines, as well as the potential to combine RNA technologies with CAR-T.
Whitepaper
Leveraging next-generation cell line development technologies for cost-effective biotherapeutic applications
Reviewing the transformative innovations within the cell line development process to help improve biotherapeutics.
Application Note
Simultaneous detection of drug efficacy and toxicity by combining HTRF, AlphaLISA, or AlphaLISA SureFire Ultra with ATPlite
This application note demonstrates how compound’s mechanism of action and potential cytotoxic effects can be deciphered thanks to the combination of AlphaLISA™, HTRF™ or AlphaLISA™ SureFire® Ultra™ immunoassays with ATPlite™ 1step cell viability assay.
Application Note
No-Wash IP1 assays are a powerful readout to characterize compounds modulating the FGFR signaling pathway in cancer drug research
This application note demonstrates that detecting the intracellular accumulation of IP1, mediated by FGFR-dependent activation of PLCγ1, can be a powerful alternative for characterizing compounds that modulate FGFR signaling in various cancer cell lines expressing FGFR1, FGFR2, and FGFR3.
Infographic
Addressing the challenges in modern biotherapeutic development
Explore next-generation approaches to enable the development and characterization of bispecific and multi-specific antibodies
Brochure
Biologics workflow solutions
Revvity can help you discover and develop high-quality biological drug products by streamlining the biologics workflow.
Looking for technical documents?
Find the technical documents you need, ASAP, in our easy-to-search library.